Neoadjuvant/ Adjuvant Chemotherapy—Are We Ready to Accept Neoadjuvant as the Gold Standard?
Seth P. Lerner, MD, argues for adopting neoadjuvant chemotherapy as the standard of care for metastatic bladder cancer patients. Dr. Lerner believes the urological community needs to define a better range of risk-stratification and more accurate diagnostic methods in order to do this. He discusses current developments in prognostic biomarkers and expression subtypes that he believes will make these necessary improvements possible.
Read More